VNRX

Volitionrx

• TipRanks·4d ago

  VolitionRx Earnings Call: Breakthroughs Amid Funding Strain

• Dow Jones·04/02 16:16

  VolitionRX Is Maintained at Buy by HC Wainwright & Co.

• Dow Jones·04/02 16:16

  VolitionRX Price Target Cut to $1.00/Share From $1.50 by HC Wainwright & Co.

• TipRanks·04/02 16:15

  VolitionRx: Robust Revenue Growth and Promising Capture-Seq Data Support Buy Rating Despite Dilution-Driven Target Cut

• TipRanks·04/02 16:11

  VolitionRx price target lowered to $1 from $1.50 at H.C. Wainwright

• Benzinga·04/02 16:06

  HC Wainwright & Co. Maintains Buy on VolitionRX, Lowers Price Target to $1

• TipRanks·04/02 14:40

  Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL), Annexon Biosciences (ANNX) and VolitionRX (VNRX)

• TipRanks·04/01 21:38

  VolitionRx Shareholders Approve Stock Issuance and Reverse Split

• Seeking Alpha·04/01 17:44

  VolitionRx anticipates France routine Nu.Q Cancer use by Q4 2026 while targeting 25%-30% 2026 cash OpEx reduction

• Seeking Alpha·04/01 10:33

  VolitionRX reports FY results

• Benzinga·03/31 20:47

  VolitionRX Q4 EPS $(0.05), Inline, Sales $447.034K Miss $765.167K Estimate

• PR Newswire·03/31 20:05

  VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

• Seeking Alpha·03/31 12:45

  VolitionRx Limited secures €2M non-dilutive funding from Belgian agencies

• Dow Jones·03/31 12:44

  VolitionRX Price Target Maintained With a $3.00/Share by D. Boral Capital

• Dow Jones·03/31 12:44

  VolitionRX Is Maintained at Buy by D. Boral Capital